8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 21, 2008)

Filed October 21, 2008For Securities:EW

Summary

This 8-K filing by Edwards Lifesciences Corporation (EW) on October 21, 2008, announces their financial results for the third quarter of 2008. The report primarily serves to furnish a press release detailing these results, which are crucial for investors to assess the company's recent performance and financial health. The filing indicates that the press release, attached as Exhibit 99.1, contains the specific financial figures. While most of the press release is furnished, certain sections (the first two paragraphs and pages 6-10) are deemed 'filed' under the Securities Exchange Act of 1934, meaning they are subject to specific SEC rules and liabilities. Investors should refer to Exhibit 99.1 for a comprehensive understanding of EW's Q3 2008 operational and financial outcomes.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on October 21, 2008, to report its third-quarter 2008 financial results.
  • 2The core of the filing is the press release (Exhibit 99.1) containing the Q3 2008 financial performance data.
  • 3Key financial results and operational updates for the third quarter of 2008 are disclosed in the accompanying press release.
  • 4Specific sections of the press release are designated as 'filed' under the Securities Exchange Act of 1934, carrying greater regulatory weight.
  • 5The filing was signed by Thomas M. Abate, Corporate Vice President, Chief Financial Officer, and Treasurer, indicating official company confirmation.
  • 6This report provides investors with timely information regarding the company's recent financial condition and results of operations.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide investors with Edwards Lifesciences Corporation's financial results for the third quarter of 2008.

The detailed financial results for the third quarter of 2008 are provided in the press release attached as Exhibit 99.1 to this 8-K filing.

No, only specific parts of the press release, namely the first two paragraphs and pages 6 through 10, are considered 'filed' under the Securities Exchange Act of 1934. The rest is furnished.

Thomas M. Abate is the Corporate Vice President, Chief Financial Officer, and Treasurer of Edwards Lifesciences Corporation. He signed the 8-K filing, confirming the accuracy of the reported information on behalf of the company.